North Stonington, CT, United States of America

Tyler J Cipriani

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tyler J Cipriani: Innovator in Macrocyclic Compounds

Introduction

Tyler J Cipriani is an innovative inventor based in North Stonington, Connecticut. He has made significant contributions to the field of medicine through his research on macrocyclic compounds. His work primarily focuses on modulating interleukin-17 (IL-17), a cytokine involved in various inflammatory diseases.

Latest Patents

Tyler has been granted one notable patent related to his research: "Macrocyclic compounds for modulating IL-17." This invention encompasses macrocyclic compounds that can affect IL-17 activity, offering potential therapeutic applications in treating inflammatory diseases and other disorders associated with IL-17.

Career Highlights

Tyler is currently affiliated with Ensemble Therapeutics Corporation, a company known for its focus on developing novel therapeutic compounds. His role at Ensemble Therapeutics has allowed him to apply his expertise in medicinal chemistry and contribute to groundbreaking research in the pharmaceutical field.

Collaborations

Throughout his career, Tyler has worked alongside talented colleagues, including Michael Taylor and Nicholas K Terrett. Their collaborative efforts have fostered an environment of innovation, driving forward the advancements in macrocyclic compounds and their therapeutic uses.

Conclusion

Tyler J Cipriani stands out as a dedicated inventor whose work is paving the way for new treatments in inflammatory diseases. His innovative approach to macrocyclic compounds exemplifies the important intersection of science and medicine, showcasing how research can lead to real-world applications that benefit society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…